• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Efficacy, safety, and retention rate of extended-release divalproex versus conventional delayed-release divalproex: A protocol for systematic review and meta-analysis.缓释双丙戊酸钠与普通迟释双丙戊酸钠的疗效、安全性和保留率：系统评价和荟萃分析方案。
Medicine (Baltimore). 2021 Dec 17;100(50):e28290. doi: 10.1097/MD.0000000000028290.
2
Efficacy, Safety, and Retention Rate of Extended-Release Divalproex Versus Conventional Delayed-Release Divalproex: A Meta-Analysis of Controlled Clinical Trials.缓释丙戊酸二钠与传统缓释丙戊酸二钠的疗效、安全性及保留率：一项对照临床试验的荟萃分析
Front Pharmacol. 2022 Apr 5;13:811017. doi: 10.3389/fphar.2022.811017. eCollection 2022.
3
Once-daily dosing is appropriate for extended-release divalproex over a wide dose range, but not for enteric-coated, delayed-release divalproex: evidence via computer simulations and implications for epilepsy therapy.每日一次给药适用于广泛剂量范围内的缓释双丙戊酸钠，但不适用于肠包衣、延迟释放的双丙戊酸钠：通过计算机模拟得出的证据及其对癫痫治疗的影响。
Epilepsy Res. 2009 Dec;87(2-3):260-7. doi: 10.1016/j.eplepsyres.2009.09.015. Epub 2009 Nov 4.
4
Absolute bioavailability and absorption characteristics of divalproex sodium extended-release tablets in healthy volunteers.丙戊酸钠缓释片在健康志愿者中的绝对生物利用度及吸收特性
J Clin Pharmacol. 2004 Jul;44(7):737-42. doi: 10.1177/0091270004266782.
5
Bioequivalence studies of a new valproic acid delayed-release capsule and divalproex sodium delayed-release tablet.一种新型丙戊酸缓释胶囊与丙戊酸钠缓释片的生物等效性研究。
Curr Med Res Opin. 2008 Jul;24(7):1869-76. doi: 10.1185/03007990802122735.
6
Comparative absorption profiles of divalproex sodium delayed-release versus extended-release tablets -- clinical implications.丙戊酸钠缓释片与长效释放片的比较吸收曲线——临床意义
Ann Pharmacother. 2006 Apr;40(4):619-25. doi: 10.1345/aph.1G617. Epub 2006 Mar 28.
7
Every-12-hour administration of extended-release divalproex in patients with epilepsy: impact on plasma valproic acid concentrations.癫痫患者每12小时服用缓释丙戊酸/divalproex：对血浆丙戊酸浓度的影响。
Epilepsy Behav. 2006 Mar;8(2):391-6. doi: 10.1016/j.yebeh.2005.12.004.
8
Conversion from delayed-release sodium valproate to extended-release sodium valproate: initial results and long-term follow-up.从丙戊酸钠缓释制剂转换为丙戊酸钠长效制剂：初步结果及长期随访
Epilepsy Behav. 2006 May;8(3):601-5. doi: 10.1016/j.yebeh.2006.02.006.
9
Does it really matter when a blood sample for valproic acid concentration is taken following once-daily administration of divalproex-ER?在每日一次服用丙戊酸缓释片后，采集用于测定丙戊酸浓度的血样的时间真的很重要吗？
Ther Drug Monit. 2006 Jun;28(3):413-8. doi: 10.1097/01.ftd.0000211814.12311.3f.
10
A study of the safety, efficacy, and tolerability of switching from the standard delayed release preparation of divalproex sodium to the extended release formulation in patients with schizophrenia.一项关于精神分裂症患者从丙戊酸钠标准缓释制剂转换为缓释剂型的安全性、有效性和耐受性的研究。
J Clin Psychopharmacol. 2004 Jun;24(3):255-9. doi: 10.1097/01.jcp.0000125687.27961.64.

引用本文的文献

1
A High-Throughput Immune-Oncology Screen Identifies Immunostimulatory Properties of Cytotoxic Chemotherapy Agents in TNBC.一项高通量免疫肿瘤学筛选确定了细胞毒性化疗药物在三阴性乳腺癌中的免疫刺激特性。
Cancers (Basel). 2024 Dec 5;16(23):4075. doi: 10.3390/cancers16234075.

缓释双丙戊酸钠与普通迟释双丙戊酸钠的疗效、安全性和保留率：系统评价和荟萃分析方案。

Efficacy, safety, and retention rate of extended-release divalproex versus conventional delayed-release divalproex: A protocol for systematic review and meta-analysis.

机构信息

Department of Special Medical, Chengdu BOE Hospital, Chengdu, Sichuan Province, China.

Department of Neurology, The Air Force Hospital of Western Theater Command, Chengdu, Sichuan Province, China.

出版信息

Medicine (Baltimore). 2021 Dec 17;100(50):e28290. doi: 10.1097/MD.0000000000028290.

DOI:10.1097/MD.0000000000028290
PMID:34918705
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8678006/
Abstract

BACKGROUND

A novel once-daily divalproex-extended release (VPA-ER) dose formulation has been developed, which prolongs therapeutic serum levels compared with that of twice-daily conventional divalproex-delayed release (VPA-DR). Currently, there is lack of meta-analysis focusing on drug retention rate between VPA-ER and VPA-DR. Thus, our study is the first one that aims to systematically examine and compare the efficacy, safety, and retention rate of VPA-ER and VPA-DR.

METHODS

Online databases including MEDLINE via PubMed, Cochrane Library, Embase (up to October 30, 2021) will be applied for literature screen. We will conduct meta-analysis by using Stata16.0 software.

RESULTS

This study aims to evaluate the efficacy, safety, and drug retention rate of VPA-ER versus conventional VPA-DR.

CONCLUSION

Once-daily VPA-ER may present a positive efficacy and not increase the incidence of AEs and has a higher retention rate for patients, which can be used as a substitute for conventional VPA-DR.INPLASY registration number: INPLASY2021110090(DOI: 10.37766/inplasy2021.11.0090).

摘要

背景

一种新型的每日一次丙戊酸钠延长释放（VPA-ER）剂量制剂已经被开发出来，与每日两次的传统丙戊酸钠延迟释放（VPA-DR）相比，它延长了治疗性血清水平。目前，缺乏专门针对 VPA-ER 和 VPA-DR 药物保留率的荟萃分析。因此，我们的研究旨在首次系统地检查和比较 VPA-ER 和 VPA-DR 的疗效、安全性和保留率。

方法

将使用在线数据库包括 MEDLINE 通过 PubMed、Cochrane 图书馆、Embase（截至 2021 年 10 月 30 日）进行文献筛选。我们将使用 Stata16.0 软件进行荟萃分析。

结果

本研究旨在评估 VPA-ER 与传统 VPA-DR 的疗效、安全性和药物保留率。

结论

每日一次的 VPA-ER 可能具有积极的疗效，不会增加不良反应的发生率，并且对患者的保留率更高，可作为传统 VPA-DR 的替代药物。INPLASY 注册编号：INPLASY2021110090（DOI：10.37766/inplasy2021.11.0090）。